Intramedullary nailing of closed tibial fracture: rhBMP2-CPM augmentation not recommended .
This report has been verified
by one or more authors of the
original publication.
Este estudio ha sido identificado como potencialmente de alto impacto.
La métrica de alto impacto de OE, impulsada por la IA, estima la influencia que probablemente tendrá un artículo integrando señales tanto de la revista en la que se publica como del contenido científico del propio artículo.
Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo.
Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(7):37 J Bone Joint Surg Am. 2013 Dec 4;95(23):2088-96. doi: 10.2106/JBJS.L.01545387 patients with closed tibial fractures were randomized in this study to investigate the efficacy and safety of the local application of recombinant human bone morphogenetic protein 2 (rhBMP-2) within a calcium phosphate matrix (CPM) in the treatment of closed tibial fractures. Participants were subject to intramedullary nail fixation in 1 of 4 treatment protocols: 1) nail fixation alone (standard of care), 2) augmented with 1.0mg/mL rhBMP-2/CPM, 3) augmented with 2.0mg/mL rhBMP-2/CPM, or 4) augmented with buffer/CPM. The study was terminated early due to futility, with a lack of efficacy in time to fracture union.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sí = 1
Incierto = 0,5
No relevante = 0
No = 0
La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.
3/4
Randomization
4/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
4/5
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.
¿Por qué se necesitaba ahora este estudio?
The standard of care for the majority of tibial fractures has become intramedullary fixation. Despite this treatment, these fractures may display delayed healing or non-union, requiring secondary intervention. Osteoconductive proteins, such as recombinant human bone morphogenetic proteins (rhBMP), have been researched as a possible adjuvant in acute fracture treatment to improve fracture and wound-healing. A factor that needs to be considered with such intervention is maintaining the osteoconductive product at the fracture site for a sufficient amount of time to stimulate healing. A calcium phosphate matrix (CPM) carrier is a newly developed product that has displayed promising preliminary results for delivery of the rhBMP to the fracture site.
¿Cuál era la pregunta principal de la investigación?
In intramedullary nailing for closed diaphyseal tibial fractures, does adjuvant rhBMP-2/CPM stimulate healing and reduce time-to-healing compared to standard of care (SOC), measured over 52 weeks postoperatively?
- Based on an interim analysis conducted after the enrollment of 180 patients, the study was terminated early due to futility (lack of efficacy in time to fracture union, p>0.476 between rhBMP-2/CPM 2.0mg/mL group and SOC only group). Of the planned 600 patients, 387 were enrolled and randomized.
- In total, 57% of patients completed the study. The majority of patients who had discontinued participation in the study did so after fracture union had already been achieved. The main reasons for discontinuation were sponsor (Wyeth) withdrawal (15%), loss to follow-up (13%), and patient request (10%).
- The median time to fracture union was similar between groups (p>0.05). Times to fracture union were 13.1 weeks in the SOC group, 13.0 weeks in the 1.0mg/mL rhBMP-2/CPM group, 15.9 weeks in the 2.0mg/mL rhBMP-2/CPM group, and 15.4 weeks in the buffer/CPM group.
- Fracture union was achieved similarly between groups: 91.5% for the SOC group, 88.8% for the 1.0mg/mL rhBMP-2/CPM group, 88.4% for the 2.0mg/mL rhBMP-2/CPM group, and 86.2% the buffer/CPM group. Delayed union and nonunion was similarly low between groups: 3-5% across groups. Hardware failure occurred most frequently in the 2.0mg/mL rhBMP-2/CPM group (14%). The rates in the other 3 groups were 6-7%.
- Groups achieved pain-free full weight-bearing at similar times. Median times to full weight-bearing were 13.4 weeks in the SOC group, 13.4 weeks in the 1.0mg/mL rhBMP-2/CPM group, 14.3 weeks in the 2.0mg/mL rhBMP-2/CPM group, and 16.4 weeks in the buffer/CPM group.
- The rate of compartment syndrome was also similarly low across groups (2-3%). The rate of grade-3 or -4 edema was low among all four groups (0-2%).
- Venous thromboembolic events occurred in 2% of the 1.0mg/mL rhBMP/CPM group, 3% of the 2.0mg/mL rhBMP/CPM group, and 2% of the buffer/CPM group, with none occurring in the SOC group. The difference was not statistically significant and the events were judged not related to rhBMP-2 intervention.
- Postoperative heterotopic ossification and calcinosis was higher among the injected groups.
¿Qué es lo que más debo recordar?
Augmentation with Recombinant human bone morphogenetic protein 2 (rhBMP-2) within a Calcium Phosphate Matrix carrier in intramedullary nail fixation for closed tibial fractures did not demonstrate any beneficial effect in time to union or time to full weight-bearing when compared to non-augmented fixation. Due to this lack of efficacy, the study was terminated early.
¿Cómo afectará esto al cuidado de mis pacientes?
The use of rhBMP-2 with a calcium phosphate matrix carrier in fixation of closed tibial fractures is not suggested based on the findings of this research. Post hoc review suggested that bioavailability of the test article may have been reduced due to changes in its preparation from the phase I to phase II/III trial. Further study may be warranted for optimizing rhBMP-2 preparations and delivery systems.
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
